Tumours shrank or stopped growing in almost one in three women (31 per cent) with low-grade serous ovarian cancer, which does ...

Almost a third (31%) of women with low-grade serous ovarian cancer, which does not respond well to chemotherapy, saw their ...

Scientists say the Royal Marsden hospitals' drug trial could change practice globally for serous form of ovarian cancer which ...

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to ...

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ...

A groundbreaking study has uncovered the origin of one of the most aggressive forms of ovarian cancer, called high-grade ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...

Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer. Now, researchers ...

H.C. Wainwright analyst Sean Lee CFA has maintained their bullish stance on VSTM stock, giving a Buy rating yesterday. Sean Lee CFA has given ...